Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments

Technology appraisal guidance
Reference number: TA852
Published: 14 December 2022

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 142 KB)

Published:

14 December 2022
Register of interests (PDF 132 KB)

Published:

14 December 2022

Final draft guidance: TA852

Final draft guidance: TA852
Final appraisal document Final draft guidance (PDF 227 KB)

Published:

10 November 2022
Committee papers (PDF 244 KB)

Published:

10 November 2022
Public committee slides (PDF 560 KB)

Published:

10 November 2022

Final draft guidance: TA669

Final appraisal document - TA669 (PDF 236 KB)

Published:

11 December 2020
Committee papers - TA669 (PDF 1.36 MB)

Published:

11 December 2020
Public committee slides - TA669 (PDF 380 KB)

Published:

11 December 2020

Draft guidance: TA669

Appraisal consultation document (PDF version) - TA669 (PDF 301 KB)

Published:

30 December 2019
Committee papers - TA669 (PDF 4.46 MB)

Published:

30 December 2019
Public committee slides - TA669 (PDF 806 KB)

Published:

30 December 2019

Invitation to participate

Final scope - TA669 (PDF 176 KB)

Published:

05 April 2019
Final stakeholder list - TA669 (PDF 212 KB)

Published:

05 April 2019
NICE's response to comments on the draft scope and provisional stakeholder list - TA669 (PDF 154 KB)

Published:

05 April 2019
Equality impact assessment (Scoping) - TA669 (PDF 122 KB)

Published:

05 April 2019

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: TA669

Draft scope post referral - TA669 (PDF 318 KB)

Published:

06 February 2019
Draft matrix post referral - TA669 (PDF 300 KB)

Published:

06 February 2019